No Data
Form 8.5 (EPT/RI)-Renalytix Plc
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.
Renalytix AI Reduces Debt With New Share Issue
Renalytix RNLX Steno Deal; CNS Pharmaceuticals CNSP NASDAQ Compliance
H.C. Wainwright Maintains Renalytix(RNLX.US) With Buy Rating, Maintains Target Price $3
H.C. Wainwright analyst Yi Chen maintains $Renalytix(RNLX.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 27.4% and a total
Renalytix Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Renalytix Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Buy Rating Justified by Renalytix AI's European Expansion and Positive Medicare Coverage
Darius Matthews : Cool. Know that they could still issue more shares due to the convertible bonds left outstanding. Also they could RS if the Acquisition doesn’t happen. Just be aware and careful. Personally, I’m long about 50 percent, staying somewhat liquid for any big dips. Happy investing